Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $151.08.
Several analysts have recently issued reports on GKOS shares. Truist Financial increased their price objective on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They issued a "buy" rating and a $182.00 price objective on the stock. BTIG Research increased their price objective on Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. JPMorgan Chase & Co. increased their price objective on Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company increased their target price on Glaukos from $145.00 to $153.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th.
Check Out Our Latest Stock Analysis on GKOS
Glaukos Stock Up 4.6 %
Shares of NYSE GKOS traded up $6.68 during mid-day trading on Thursday, hitting $153.06. The company had a trading volume of 747,257 shares, compared to its average volume of 495,754. The company has a market capitalization of $8.44 billion, a PE ratio of -50.68 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos has a 1-year low of $83.90 and a 1-year high of $163.71. The business's 50-day simple moving average is $151.66 and its 200 day simple moving average is $138.37.
Insiders Place Their Bets
In related news, COO Joseph E. Gilliam sold 3,328 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Glaukos
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. acquired a new stake in Glaukos in the third quarter valued at about $25,000. IFP Advisors Inc acquired a new stake in Glaukos in the fourth quarter valued at about $43,000. Asset Planning Inc acquired a new stake in Glaukos in the fourth quarter valued at about $90,000. Picton Mahoney Asset Management acquired a new stake in Glaukos in the fourth quarter valued at about $125,000. Finally, Harvest Fund Management Co. Ltd lifted its position in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 860 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.
Glaukos Company Profile
(
Get Free ReportGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
